GeneDx

GeneDx is a genomics company based in Stamford, Connecticut, specializing in rare disease diagnostic testing, particularly for pediatric and neonatal intensive care unit (NICU) cases. Founded in 2000, the company has over two decades of experience in genetic sequencing and is recognized for its leadership in next-generation sequencing (NGS) diagnostics. GeneDx became publicly traded on Nasdaq under the ticker WGS in January 2023. The company offers a range of diagnostic testing services, including whole exome and genome sequencing, and advanced clinical interpretation using a proprietary platform. GeneDx utilizes one of the largest rare disease datasets, with over 750,000 exomes and genomes sequenced, to enhance diagnostic accuracy and support drug discovery. It collaborates with healthcare providers to deliver targeted care plans and emphasizes the importance of early diagnosis and personalized treatment for patients, particularly children with undiagnosed genetic conditions. GeneDx is committed to improving health outcomes through genetic insights and innovative healthcare solutions.